A summary slide of the TRIUMPH-1 retatrutide data presented today by Dr. Ania Jastreboff at #ADA2026 🚨 TRIUMPH-1: Phase 3 Obesity Trial with Retatrutide 🚨 Retatrutide 💉, a once-weekly triple hormone receptor agonist. 📅 80 weeks (20 months) | 12 mg ⬇️ 28.3% average body weight reduction ⚖️ 70.3 lbs (31.9 kg) lost 📈 Participants in Extension lost up to 30% (85 lbs) on average at 104 weeks 🎯 Weight Reduction Thresholds ✅ Nearly all lost ≥5% ✅ Over 85% lost ≥15% ✅ More than 1 in 4 lost ≥35% 📏 Anthropometric Treat-to-Target 🔵 BMI <30 → 2/3 🔵 BMI <25 → 1/3 📅 At 80 weeks | 4 mg (just 1 titration step) → 19% body weight reduction 🩺 Health Outcomes 🦵 Knee OA: >70% reduction in WOMAC pain subscale 😴 OSA: >60% reduction in AHI 🩸 Prediabetes reverted to normoglycemia in >95% of participants ⬇️ TG 41.0% | LDL 19.6% | SBP 12.3 mmHg ⚠️ Safety 🤢 Most common side effects were gastrointestinal, more frequent with RETA 9 & 12 mg 📉 Reported hypotension more common with RETA in participants on antihypertensive meds 🚽 UTIs more common with RETA, occurring mostly in female participants #ADASciSessions #Obesity #Retatrutide

These numbers are shocking. It's like we got a new frontier AI model but for the body. Lilly's phase 3 results for retatrutide: > highest dose lost 28.3% of body weight in 80 wks > 70 lbs ave > 45% lost 30% or more of their body weight > 65% on the top dose no longer clinically obese Retatrutide is more dynamic than semaglutide and tirzepatide because it targets three receptors (GIP, GLP-1, and glucagon), versus one and two, respectively. Side effects, on the highest dose (12mg), were higher for retatrutide than tirzepatide (nausea and GI), with an 11.3% drop out rate. The lowest 4mg dose still delivered 19% loss with fewer dropouts than placebo.

Today, we took long-overdue action to restore science, accountability, and the rule of law. In September 2023, the Biden FDA pushed a number of peptides into Category 2 — “Bulk Drug Substances that Raise Significant Safety Risks” — driving a dangerous black market that puts Americans at risk. Now, after nominators withdrew 12 peptides, the FDA will remove them from Category 2 and will bring them to PCAC at its next two meetings, beginning in July—where independent experts will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence. • BPC-157 • Thymosin beta-4 fragment (LKKTETQ) • Epitalon • GHK-Cu (injectable) • MOTS-c • DSIP (Emideltide) • Dihexa Acetate • Ibutamoren Mesylate • Melanotan II • KPV • Semax (heptapeptide) • Cathelicidin LL-37 This action begins to restore regulated access and will immediately begin shifting demand away from the black market. We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve.

GLP-1’s don’t simply cause you to eat less. They reduce inflammation, reduce cancer, improve arthritis pain, reduce alcohol consumption, protect the heart independent of weight loss, stimulate beta cells in the pancreas, keep you from developing type 2, and generally reduce all cause mortality. 😮‍💨 So no, you can’t just “eat less” and get the same benefits.

🚨 BREAKING: FDA APPROVES ELI LILLY GLP-1 PILL $LLY $NVO $HIMS

Peptide Sciences, arguably one of the largest research peptide vendors, just announced they’re shutting down. That’s a pretty big deal considering how long they’ve been around. It also likely won’t be the last. As compounding pharmacies gain clearer pathways to prescribe peptides, the old “research peptide” vendor model becomes harder to sustain. A few things worth knowing: - This doesn’t mean peptides are going away - Some gray-market vendors will likely disappear - New ones will also show up quickly When a big vendor disappears, the market doesn’t disappear. It fragments.

Expect a massive surge in compounding pharmacies, explicit warning labels on gray market peptides (currently is “not for human use”… ) and steep penalties for any venue besides Lilly selling Retatrutide. And per prediction, NIH budget to be increased 1%. More on that soon…

Expect a massive surge in compounding pharmacies, explicit warning labels on gray market peptides (currently is “not for human use”… ) and steep penalties for any venue besides Lilly selling Retatrutide. And per prediction, NIH budget to be increased 1%. More on that soon…

RFK Jr. was just on Joe Rogan’s podcast and said ~14 peptides currently restricted under the FDA’s Category 2 list could soon be eligible for legal compounding again. If implemented, that would materially EXPAND peptide access in the U.S. Category 2 status currently restricts compounding due to safety concerns. Moving substances to Category 1 would allow regulated U.S. pharmacies to compound them under oversight, potentially reducing reliance on unregulated sourcing. Access expansion changes behavior quickly. If more peptides become legally compoundable, we’ll likely see: - More first-time users - More stacking - Faster experimentation - More telehealth activity But increased availability doesn’t automatically improve outcomes. More compounds in circulation often means: - Overlapping protocols - Escalation mistakes - Inconsistent cycles - Less clarity on what’s actually working Regulatory shifts may improve supply chain oversight. They don’t replace execution discipline. Whether 14 peptides move or not, one variable remains constant: Outcomes depend on structured use. Clear protocols. Intentional dosing. Consistent tracking. If peptide access expands, structured protocol management becomes even more important. That’s exactly why PepTracker exists.

Lilly’s oral GLP-1 (orforglipron) outperformed oral semaglutide in A1C and weight loss in a head-to-head T2D trial published in The Lancet. This is meaningful comparative data. But let’s add some context… 👇

> Peptides > Claude Code > Diet Cokes > America We are truly amidst history’s greatest timeline

Retatrutide reduces body fat by 24% in 24 weeks while PRESERVING muscle mass. Not Ozempic. Not Mounjaro. This is a triple agonist: GLP-1 GIP glucagon receptor. Clinical trial, 48 weeks: • Body weight: -24.2% average • Fat loss: significant • Lean muscle mass: PRESERVED • Metabolic markers: dramatically improved Here’s why this is different: Ozempic/Mounjaro = dual agonists (GLP-1 GIP) → Suppress appetite → You eat less → Lose weight but also muscle Retatrutide = adds glucagon receptor → Suppresses appetite AND → Activates fat burning directly → Body uses fat for fuel instead of breaking down muscle Blood work improvements tracked in trials: • Fasting glucose: normalized • Triglycerides: -40% • Inflammatory markers: reduced • Insulin sensitivity: significantly improved The metabolic difference: Dual agonists: Force you to eat less (suffer through hunger, lose muscle) Retatrutide: Reprograms metabolism to PREFER burning fat (appetite controlled, muscle preserved) DEXA scans in the study confirmed: Fat mass dropped dramatically. Lean mass stayed intact. This isn’t starvation weight loss. This is your body finally burning stored fat the way it’s supposed to. Typical dosing protocol: Start 2mg weekly, titrate up to 8-12mg based on tolerance. Compare the outcomes: • Ozempic: 15% weight loss, muscle loss common, nausea frequent • Retatrutide: 24% fat loss, muscle preserved, better tolerance profile One forces calorie restriction. The other fixes fat metabolism.

“My notes app filled with random ideas I had in the shower and a half-finished grocery list is totally the best place to track my peptide use” …is what nobody should be saying when we exist 💉🗒️

🚨 BREAKING: Sen. Tom Cotton is demanding the FDA investigate whether illegal Chinese drug ingredients are entering the U.S. through compounded weight-loss meds, warning of serious public health and national security risks.

🚨 BREAKING: Sen. Tom Cotton is demanding the FDA investigate whether illegal Chinese drug ingredients are entering the U.S. through compounded weight-loss meds, warning of serious public health and national security risks.